Valuation: CSL Limited

Capitalization 56.73B 48.58B 45.18B 42.12B 78.7B 5,113B 84.41B 520B 205B 2,446B 213B 208B 8,969B P/E ratio 2026 *
22.5x
P/E ratio 2027 * 16.5x
Enterprise value 65.49B 56.08B 52.15B 48.62B 90.84B 5,902B 97.44B 601B 236B 2,824B 246B 241B 10,353B EV / Sales 2026 *
4.1x
EV / Sales 2027 * 3.87x
Free-Float
99.9%
Yield 2026 *
2.62%
Yield 2027 * 2.85%
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.02%
1 week+2.99%
Current month+0.39%
1 month-3.34%
3 months-16.97%
6 months-28.26%
Current year+0.39%
More quotes
1 week 168.65
Extreme 168.65
175.86
1 month 168.29
Extreme 168.29
183.31
Current year 168.29
Extreme 168.29
175.86
1 year 168
Extreme 168
282.2
3 years 168
Extreme 168
314.28
5 years 168
Extreme 168
319.78
10 years 91.62
Extreme 91.62
342.75
More quotes
Manager TitleAgeSince
Chief Executive Officer 60 06/03/2023
Director of Finance/CFO 52 07/10/2025
Chief Tech/Sci/R&D Officer 64 01/10/2020
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 14/08/2013
Director/Board Member 68 16/02/2016
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.02%+2.99%-38.10%-38.75% 56.73B
-3.58%+0.62%+10.21%+7.48% 78.8B
-0.37%+87.80%+87.80%+87.80% 58.65B
+0.44%+7.71%+32.29%+224.44% 55.89B
-1.06%+6.30%+24.73%-35.56% 27.23B
-0.51%+4.46%+50.74%+32.17% 20.87B
-0.11%+6.88%+163.96%+125.06% 19.74B
+6.79%+11.82%+65.11%+1,364.18% 17.33B
-0.53%+4.66%+164.24%+781.19% 14.81B
-0.04%-.--%+39.00%+171.78% 14.02B
Average +0.00%+5.05%+60.00%+271.98% 36.41B
Weighted average by Cap. -0.74%+4.76%+40.30%+153.48%
See all sector performances

Financials

2026 *2027 *
Net sales 15.98B 13.68B 12.73B 11.86B 22.17B 1,440B 23.78B 147B 57.62B 689B 59.93B 58.7B 2,526B 16.7B 14.3B 13.3B 12.4B 23.17B 1,506B 24.85B 153B 60.23B 720B 62.64B 61.36B 2,641B
Net income 2.58B 2.21B 2.05B 1.91B 3.58B 232B 3.84B 23.65B 9.3B 111B 9.67B 9.47B 408B 3.43B 2.94B 2.73B 2.55B 4.76B 309B 5.1B 31.46B 12.37B 148B 12.86B 12.6B 542B
Net Debt 8.76B 7.5B 6.97B 6.5B 12.15B 789B 13.03B 80.32B 31.57B 378B 32.84B 32.16B 1,384B 7.86B 6.73B 6.26B 5.84B 10.9B 708B 11.69B 72.1B 28.34B 339B 29.48B 28.87B 1,243B
More financial data * Estimated data
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Employees
29,904
More about the company
Date Price Change Volume
13/01/26 173.32 $ -1.02% 682,808
12/01/26 175.10 $ +0.46% 573,969
09/01/26 174.29 $ -0.09% 740,858
08/01/26 174.45 $ +2.62% 944,446
07/01/26 170.00 $ +1.02% 1,039,843

Delayed Quote Australian S.E., 13 January 2026 at 04:14 pm AEDT

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
117.68USD
Average target price
156.54USD
Spread / Average Target
+33.02%
Consensus

Quarterly revenue - Rate of surprise